Adagio Medical shares surge 17.70% intraday after publishing pre-clinical results showing 50-75% reduction in ablation time with next-gen ULTA catheter.

Adagio Medical (Nasdaq: ADGM) surged 17.70% intraday following the publication of pre-clinical results for its next-generation ULTA catheter, showcasing a potential 50-75% reduction in ablation time and improved handling characteristics. The study, authored by physicians from leading European and Canadian cardiac programs, underscores the technology’s enhanced efficiency and compatibility with standard procedures, aligning with the company’s strategy to advance ventricular arrhythmia treatments. CEO Todd Usen highlighted the innovation’s potential to improve procedural efficiency while retaining core advantages of ULTA’s prior generation. The second news event, a Benzinga headline, provided minimal additional context. The stock’s sharp rise directly correlates with the positive clinical data and strategic advancements detailed in the first announcement.